China Resources Medicine "eats" stomach-churning tablets

After four months, China Resources Medicine finally wanted to "eat" the stomach-churning tablets.
On the evening of September 17th, Jiang Zhong Pharmaceuticals announced that the parties had failed to agree on a plan to increase the capital of Jiang zhong Group on the premise and basis of the 29.28 percent stake in Jiang zhong group held by China Resources Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as China Resources Pharmaceutical Holdings) by Dalian Group Co., Ltd. Iron heart to "eat" stomach-churning tablets of China Resources Medicine do not want to wait any longer, to pay Jiang zhong group this time all the new registered capital.
Pharmaceutical Holdings is a wholly owned subsidiary of China Resources Pharmaceuticals. "Daily Economic News" reporter learned that after the completion of the capital increase, China Resources Pharmaceutical Holdings will hold a 51% stake in Jiang zhong group, thereby indirectly controlling jiang chinese medicine has issued shares of 43.03 percent. China Resources Pharma will greatly strengthen its own layout in the OTC drug market, and in recent years, the lack of new growth point of the performance of The Chinese medicine industry has found a big backing.reorganization lasted four months
on the evening of September 17, Jiang Traditional Chinese Pharmaceuticals announced that China Resources Pharmaceutical Holdings would recognize all of Jiang zhong group's new registered capital. Upon completion of the capital increase, China Resources Pharmaceutical Holdings will hold a 51% stake in Jiang zhong group and indirectly control 43.03% of the shares issued by Jiang Chinese medicine.
, China Resources Pharmaceuticals into the main Jiang traditional Chinese medicine industry restructuring took four months to finally land. Earlier in May, China Resources Pharmaceuticals announced that it was ready to establish a long-term cooperative relationship with the Jiangxi provincial government to promote the development of the pharmaceutical industry in Jiangxi province. It is proposed to work with the Jiangxi provincial government to restructure Jiangzhong Group and realize the company's controlling interest in Jiangzhong Group.
Subsequently, Jiang Zhong Pharmaceuticals disclosed that China Resources Pharmaceutical Group will take a 51% or more stake in Jiang zhong group by purchasing a part of Jiang zhong group and increasing its capital by cash or assets.
on May 16, Jiangzhong Pharmaceuticals disclosed a major asset restructuring, and the company is planning to acquire a controlling stake in China Resources Jiangxi Pharmaceutical Co., Ltd. (hereinafter referred to as China Resources Jiangxi), a controlling stake in Jiangxi Nanchang Sanghai Pharmaceutical Co., Ltd. (hereinafter referred to as Sanghai Pharmaceuticals) and a controlling stake in Jiangxi Nanchang Jisheng Pharmaceutical Co., Ltd. (hereinafter referred to as Jisheng Pharmaceuticals). Jiangzhong Pharmaceutical Securities Department in an earlier interview with the "Daily Economic News" reporter said that the acquisition of China Resources Pharmaceutical assets, and China Resources Pharmaceuticals and Jiangxi Province SASAC equity transfer matters are independent of each other, the acquisition of China Resources Pharmaceuticals assets is a strategic cooperation with China Resources Pharmaceuticals, in line with the company's development strategy.
on August 1st, Jiangzhong Pharmaceuticals terminated a major asset restructuring and moved to a general acquisition of a 51% stake in Sanghai Pharmaceuticals and Jisheng Pharmaceuticals. The abandonment of the acquisition of China Resources Pharmaceuticals Commercial Holdings of 70% of China Resources Jiangxi, because the latter's original shareholders have not fulfilled the previous share transfer performance commitments.is expected to break through the performance "ceiling
for the average consumer, compared to China Resources Pharmaceuticals, to stomach-churning tablets and grass coral tablets and other over-the-counter drug business (hereinafter referred to as OTC business) as a representative of Jiang Chinese medicine industry visibility or higher.
2015-2017, Jiang's Chinese medicine industry achieved revenues of 2.597 billion yuan, 1.562 billion yuan and 1.747 billion yuan, respectively. Its star products, stomach-churning tablets, generated revenues of 1,073 million yuan, 1,020 million yuan and 1,096 million yuan, respectively, in the three years. According to the company, Jiang Zhong brand stomach-churning tablets won the 2017 Chinese over-the-counter drug products "Chinese medicine digestion class" first place.
Today, Jiang Chinese Medicine is about to become the fifth listed company of China Resources Pharmaceuticals, which previously owned China Resources 39, China Resources Shuanghe, Dong A gum, while China Resources Pharmaceuticals is also listed on the Hong Kong Stock Exchange, China Resources Group is also a Hong Kong-listed hospital group China Resources Phoenix Medical's single major shareholder.
chinese medicine industry, China Resources Pharma will strengthen its pharmaceutical industry sector, especially in the field of over-the-counter drugs and health care products.
for Jiang's Chinese medicine industry, this welcome to the new owner of China Resources Pharmaceuticals, or will be its breakthrough in recent years encountered the best opportunity to achieve the ceiling of performance. Previously, Jiang Chinese medicine industry relies on the main business OTC pharmaceutical and Chinese medicine and health care products, performance has long been difficult to have significant growth.
Jiangjiang Chinese Medicine Securities Department staff in an interview with the Daily Economic News, said that the company still maintained the previous strategic deployment and development direction, "China Resources into the management may be based on the strategic direction of China Resources Pharmaceuticals to make certain adjustments."
to the "ceiling" of the company's performance in recent years, Jiang said the company is also carrying out extended mergers and acquisitions and internal expansion, open source savings to boost revenue and profit scale. Previously disclosed acquisitions of controlling stakes in Sanghai Pharmaceuticals and Jisheng Pharmaceuticals are also progressing steadily.
the restructuring, the "Daily Economic News" reporter also called China Resources Pharma's public phone, but as of the time of writing, could not get in touch. (Daily Economic News)